CONy 2022 | Unanswered questions in ALS research

Clive Svendsen, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, comments on future lines of research within the field of amyotrophic lateral sclerosis (ALS). Current drugs only aim to prolong the lives of patients with ALS and Dr Svendsen emphasizes the need to elucidate the pathology of the disease on a cellular level, which the Answer ALS initiative aims to achieve. Whilst approximately 10% of cases of a genetic origin, mainly via mutations in the C9orf72 gene, understanding the cause of non-genetic ALS will lead to curative therapies. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.